

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Announcement

List of NeuroSearch announcements in 2008 and in January - March 2009

In accordance with section 27a of Consolidated Act about Securities Trading etc., we hereby issue a complete list of NeuroSearch announcements in 2008 and in January - March 2009. All announcements are available under the IR section of our homepage www.neurosearch.com.

Date	No.	Heading
04.01.2008	01-08	NeuroSearch announces the end of stabilisation period in connection with the rights issue, completed November 2007
17.01.2008	02-08	NeuroSearch issues 185,755 new shares to the sellers of Carlsson Research AB as milestone payment relating to the start of ACR343 Phase I study
22.01.2008	03-08	NeuroSearch announces revised financial calendar for 2008
23.01.2008	04-08	NeuroSearch has issued 185,755 new shares in a directed issuance to the sellers of Carlsson Research AB
31.01.2008	05-08	NeuroSearch A/S' share capital and voting rights
03.03.2008	06-08	NeuroSearch publishes positive and confirmatory results from TIPO-2, a clinical metabolic study with tesofensine for the treatment of obesity
04.03.2008	07-08	NeuroSearch A/S - Financial statements 2007
06.03.2008	08-08	List of NeuroSearch announcements in 2007 and in January - March 2008
11.03.2008	09-08	NeuroSearch issues new shares in connection with exercise of warrants
31.03.2008	10-08	NeuroSearch initiates clinical Phase I study with NSD-788 for the treatment of anxiety and depression
31.03.2008	11-08	NeuroSearch A/S' share capital and voting rights
15.04.2008	12-08	Changes in the board of directors of NeuroSearch A/S
15.04.2008	13-08	Notice convening ordinary general meeting in NeuroSearch
25.04.2008	14-08	NeuroSearch initiates pivotal Phase III programme with ACR16 for the treatment of Huntington's disease
28.05.2008	15-08	Notice concerning proxies received for the Annual General Meeting of NeuroSearch A/S
30.04.2008	16-08	NeuroSearch A/S – Q1 Report 2008
30.04.2008	17-06	Report on ordinary general meeting held in NeuroSearch A/S
05.05.2008	18-08	Notice convening Extraordinary General Meeting in NeuroSearch A/S
21.05.2008	19-08	NeuroSearch has decided to issue 300,000 new shares in a directed offering subscribed for by institutional investors at a price of DKK 280 per share to finance a milestone payment to the sellers of Carlsson Research AB
21.05.2008	20-08	NeuroSearch releases time schedule for the completion of

		the directed offering of 300,000 new shares subscribed for by institutional investors to finance a milestone payment to the sellers of Carlsson Research AB
21.05.2008	21-08	The shareholdings of A.J. Aamund in NeuroSearch is diluted to less than 5% in connection with the company's issue of 300,000 new shares
23.05.2008	22-08	Report on extraordinary general meeting held in NeuroSearch A/S
26.05.2008	23-08	NeuroSearch has issued 300,000 new shares in a directed offering subscribed for by institutional investors to finance a milestone payment related to the initiation of a Phase III study with ACR16 in Huntington's disease
30.05.2008	24-08	NeuroSearch A/S' share capital and voting rights
20.06.2008	25-08	NeuroSearch announces positive key results from a Phase II study with ABT-894 in adults with Attention Deficit-Hyperactivity Disorder (ADHD)
26.06.2008	26-08	NeuroSearch successfully completes Phase I with ACR325 and announces the decision to progress development into Phase II Proof-of-Concept studies in Parkinson's disease and Bipolar Disorder
08.07.2008	27-08	NeuroSearch's TIPO-4 study with tesofensine confirms the efficacy in weight management previously reported in TIPO-1 and provides the first long-term data with an average weight loss of 13 to 14 kg
10.07.2008	28-08	NeuroSearch receives an IND approval from the FDA for ACR16 as part of an ongoing pivotal clinical programme in Huntington's disease
11.08.2008	29-08	NeuroSearch reports final results from the TIPO-2 study with tesofensine in obesity
27.08.2008	30-08	NeuroSearch announces revised financial calendar for 2008
27.08.2008	31-08	NeuroSearch A/S – Interim report for the first half-year of 2008
09.09.2008	32-08	NeuroSearch issues new shares in connection with exercise of warrants
30.09.2008	33-08	NeuroSearch A/S' share capital and voting rights
27.10.2008	34-08	NeuroSearch announces the dosing of the first patients in the US HART study, a part of the ongoing ACR16 pivotal programme in Huntington's disease
17.11.2008	35-08	NeuroSearch A/S – Q3 report 2008
26.11.2008	36-08	NeuroSearch announces highly positive and supportive final results from a cardiovascular safety evaluation study with the anti-obesity drug tesofensine
23.12.2008	37-08	NeuroSearch announces financial calendar for 2009
29.01.2009	01-09	NeuroSearch announce an expansion to their existing alliance with GlaxoSmithKline
11.02.2009	02-09	NeuroSearch announces results from Phase II studies of ABT-894 in diabetic neuropathic pain
17.02.2009	03-09	NeuroSearch announces drug discovery and development alliance with Eli Lilly and Company
23.02.2009	04-09	NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression
02.03.2009	05-09	NeuroSearch regains global rights to ACR16

03.03.2009	06-09	NeuroSearch has issued 530,745 new shares in a directed offering subscribed by Eli Lilly and Company in connection with the signing of a drug discovery and development alliance
04.03.2009	07-09	NeuroSearch A/S Financial Statements 2008

Flemming Pedersen
CEO

Contact person:

Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications, telephone: +45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq OMX Copenhagen. The company's core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial share of NeuroSearch's activities is partner financed through an alliance with Eli Lilly and Company and collaborations with GlaxoSmithKline (GSK) and Abbott. The drug pipeline comprises 8 clinical (Phase I-III) development programmes: ACR16 for Huntington's disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR325 for Parkinson's disease (Phase II ready), ABT-107 and ABT-560 for the treatment of various CNS disorders – both (Phase I) in collaboration with Abbott, ACR343 for schizophrenia (Phase II ready) and NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.